CDK4 and melanoma: While CDK4/6 inhibitor combinations with PD‐1 monoclonal antibodies have only recently gained attention in head and neck squamous cell carcinoma (HNSCC) with no mature 5‐year overall survival (OS) data available, such strategies have been extensively explored in other malignancies including melanoma and breast cancer.